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Abstract
Background: Medication adherence is vital to ensuring optimal patient outcomes, par-
ticularly amongst multimorbid older people prescribed multiple medications. 
Interventions targeting adherence often lack a theoretical underpinning and this may 
impact on effectiveness. The theoretical domains framework (TDF) of behaviour can 
aid intervention development by systematically identifying key determinants of medi-
cation adherence.
Objectives: This study aimed to (i) identify determinants (barriers, facilitators) of ad-
herence to multiple medications from older people’s perspectives; (ii) identify key do-
mains to target for behaviour change; and (iii) map key domains to intervention 
components [behaviour change techniques (BCTs)] that could be delivered in an inter-
vention by community pharmacists.
Method: Focus groups were conducted with older people (>65 years) receiving ≥4 
medications. Questions explored the 12 domains of the TDF (eg “Knowledge,” 
“Emotion”). Data were analysed using the framework method and content analysis. 
Identification of key domains and mapping to intervention components (BCTs) fol-
lowed established methods.
Results: Seven focus groups were convened (50 participants). A wide range of deter-
minants were identified as barriers (eg forgetfulness, prioritization of medications) and 
facilitators (eg social support, personalized routines) of adherence to multiple medica-
tions. Eight domains were identified as key targets for behaviour change (eg “Social 
influences,” “Memory, attention and decision processes,” “Motivation and goals”) and 
mapped to 11 intervention components (BCTs) to include in an intervention [eg “Social 
support or encouragement (general),” “Self- monitoring of the behaviour,” “Goal- setting 
(behaviour)”].
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1  | BACKGROUND
Adherence to medications, whereby patients take (or use) their med-
ication in agreement with the recommendations of their clinicians, is 
vital to ensuring optimal patient outcomes. Adherence is of particular 
clinical importance in older adults (conventionally those ≥65 years).1 
This is because older people often suffer from two or more long- term 
conditions (ie multimorbidity)2 and, therefore, require treatment with 
multiple medications.3-5
Non- adherence to prescribed regimens can result in negative clin-
ical outcomes for older patients, as well as increased use of health- 
care resources (eg increased contact with primary health- care teams, 
emergency department visits, hospitalizations) and higher associated 
costs (eg medication wastage).1,6 Globally, it is estimated that med-
ication non- adherence results in annual avoidable costs of approxi-
mately US$270 billion.7 The scale of the problem is considered to be 
equivalent to a major disease epidemic and therefore continues to be a 
key priority for policymakers, researchers and health- care profession-
als (HCPs) worldwide.6,8 Despite variation in estimated rates of non- 
adherence in older adults (range 25%- 75%),9 it is clear that there is 
considerable potential for improvement in this population group.
Adherence is a complex behaviour, and, to date, interventions have 
shown only limited effectiveness in terms of improving both medica-
tion adherence and clinical outcomes.10-12 For example, a recent up-
date of a Cochrane review involving 182 randomized controlled trials 
found that a minority of trials, deemed to be at low risk of bias, reported 
improvements in both medication adherence and clinical outcomes in 
the intervention groups.10 The review authors supported the use of 
complex interventions when targeting adherence; however, they also 
highlighted the difficulties surrounding the reproducibility of interven-
tion design and delivery. For example, the specific components of the 
interventions were often poorly described in published reports, making 
replication and potential implementation into clinical practice challeng-
ing. Another systematic review13 that focussed specifically on theory- 
based adherence interventions targeting older adults prescribed four 
or more medications identified a limited number of studies, most of 
which lacked a robust theoretical underpinning (ie an in- depth under-
standing of exactly how the individual components of the intervention 
will bring about a change in behaviour). The absence of a theoretical 
base in adherence interventions has been identified as a factor that 
may be affecting intervention success and effectiveness.10,13
To overcome these limitations, this study followed the UK Medical 
Research Council’s (MRC) framework for complex interventions.14 As 
part of initial intervention development work, the MRC recommends 
that researchers identify existing evidence and establish the inter-
vention’s theoretical basis. The aforementioned systematic review of 
theory- based adherence interventions delivered to older adults receiv-
ing multiple medications13 highlighted a lack of published interventions 
with a robust theoretical underpinning in this area. The study reported 
here aimed to explore older people’s adherence behaviour using the 
theoretical domains framework (TDF)15 as the underpinning model of 
theoretical determinants of behaviour. The TDF acts as a theoretical lens 
through which key determinants (ie theoretical domains) of the target 
behaviour (ie medication adherence) can be identified for targeting with 
a behaviour change intervention.16 Key theoretical domains can then 
be mapped to appropriate behaviour change techniques (BCTs).17,18 
The selected BCTs form the “active ingredients” of the intervention and 
are used to bring about the required changes in the target behaviour. 
This approach offers a robust, systematic and theory- based approach 
to selecting and specifying components of a complex behaviour change 
intervention.19 Therefore, the objectives of this study were to (i) identify 
determinants (ie barriers and/or facilitators) of adherence to multiple 
medications from the viewpoint of older adults; (ii) select key TDF do-
mains to target to achieve desired changes; and (iii) map key domains to 
appropriate BCTs (intervention components) that could be included in an 
intervention that could feasibly be delivered by community pharmacists.
2  | METHODS
This study formed part of a multiphase research project that aimed to 
improve treatment outcomes in older patients by targeting HCPs’ clin-
ical behaviours [ie appropriate prescribing and dispensing of polyphar-
macy (≥4 medications5) by general practitioners (GPs) and community 
pharmacists]20,21 and patients’ medication adherence behaviours. It 
was intended at the outset of the project that any intervention to 
improve adherence to multiple medications in older people in pri-
mary care would be delivered by community pharmacists. This was 
because, in addition to being readily accessible to patients, two recent 
Cochrane reviews support pharmacists’ involvement in interventions 
to improve patients’ use of medications.10,22 To explore the behaviour 
of interest (adherence to multiple medications) in detail, focus groups 
were conducted with older people who were prescribed four or more 
regular medications using a TDF- based topic guide.
Ethical approval was granted by the Office of Research Ethics 
Committees for Northern Ireland (REC reference 13/NI/0114).
Conclusion: This study used a theoretical underpinning to identify potential interven-
tion components (BCTs). Future work will incorporate the selected BCTs into an inter-
vention that will undergo feasibility testing in community pharmacies.
K E Y W O R D S
adherence, behaviour change, community pharmacy, intervention, polypharmacy, qualitative, 
theoretical domains framework
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2.1 | Sampling and recruitment strategy
General practices that had previously participated in a linked study 
(Cadogan et al.20) were approached and asked if they would facilitate 
patient recruitment into this study. General practices from across the 
five Health and Social Care Trusts in Northern Ireland were sampled 
using a purposive sampling approach. Patient recruitment within 
each practice was overseen by the Northern Ireland Clinical Research 
Network (NICRN). Inclusion criteria were as follows: patients aged 
over 65 years, resident in the community, prescribed four or more 
regular medications and not cognitively impaired. Nurse practitioners 
from the NICRN screened practice records and issued written invita-
tion letters to patients who met the inclusion criteria. A reply slip was 
included with the invitation letter. Patients interested in taking part 
in the study were asked to return the reply slip to a member of the 
research team (CC) who then made follow- up contact with patients.
One focus group was scheduled per practice after an adequate 
number of patients (five patients minimum; 10 patients maximum) 
confirmed that they could attend. Written informed consent was ob-
tained from all participants before each focus group was convened. 
Participants were offered an honorarium of £50 for participating in 
the study.
2.2 | Focus groups
Focus groups were convened by two members of the research team 
who acted as moderator (CC) and note- taker (DP), respectively. Focus 
groups were held between October 2014 and January 2015, either at 
the patients’ general practice or at another convenient location, (eg 
local community centre). A semi- structured topic guide was devel-
oped by the research team which included a health psychologist (JF) 
with expert knowledge of the TDF.23 In developing the focus group 
topic guide, the research team made the decision to use the original 
12- domain version of the framework (TDF1)15 rather than the more 
recent 14- domain version (TDF2).24 This decision was based on the 
research team’s discussion of the importance of the “Nature of the 
behaviours” domain in the context of older people’s adherence be-
haviour, as previous research has described this behaviour as “rou-
tine.”25 As the “Nature of the behaviours” domain was thus deemed 
likely to be important to the target behaviour (ie adherence to multiple 
medications) and is absent from TDF2,24 TDF115 was selected as the 
theoretical framework for the current study.
Key interview questions (Appendix S1) were developed based on 
each of the 12 theoretical domains that were included in the origi-
nal version of the framework (TDF1): “Knowledge,” “Skills,” “Social/
professional role and identity,” “Beliefs about capabilities,” “Beliefs 
about consequences,” “Motivation and goals,” “Memory, attention and 
decision processes,” “Environmental context and resources,” “Social 
influences,” “Emotion,” “Behavioural regulation” and “Nature of the be-
haviours.”15 Further descriptions of each theoretical domain are pro-
vided in Appendix S2. For example, in relation to the “Motivation and 
goals” domain, patients were asked “How important is it to you to take all 
of your different medicines as the GP has instructed/directed/prescribed?” 
Prompts were also included to elicit further information from partici-
pants where necessary.
With participants’ consent, each focus group was digitally re-
corded, transcribed verbatim and checked for accuracy. Patient iden-
tifiers were removed, and an anonymous code was assigned to each 
participant.
2.3 | Data analysis
Data analysis comprised three stages: (i) identification of determinants 
(barriers, facilitators) of adherence, (ii) identification of key TDF do-
mains to target for behaviour change and (iii) mapping of key TDF 
domains to BCTs (intervention components). Figure 1 provides an 
overview of these three stages with further details provided in the 
text below.
2.3.1 | Stage 1: Identification of determinants 
(barriers, facilitators) of adherence
The framework method was used to systematically index and chart 
data into a framework matrix.26 TDF1 was used as the analytical 
framework whereby each of the 12 domains served as the coding 
categories.15 Following transcription of focus group recordings, an 
in- depth familiarization process was undertaken through repeated 
reading of transcripts, as well as listening to audio recordings. Each 
transcript was coded independently by at least two members of the 
research team (DP, CR, CH). Coding was compared and agreed be-
tween the coders, and any discrepancies were resolved by discussion. 
The data were managed using NVivo QSR 10 before being imported 
into a Microsoft Excel spreadsheet to generate a framework matrix.
Content analysis was then performed inductively on the frame-
work matrix to identify emerging themes relating to barriers and fa-
cilitators (ie determinants) of adherence within each TDF domain. A 
summary of the content analysis was reviewed by three members 
of the research team (DP, CR, CH), and content themes were agreed 
upon.
2.3.2 | Stage 2: Identification of key TDF domains to 
target for behaviour change
The second stage of data analysis involved identifying key domains 
to target with an intervention.27 To date, qualitative TDF- based stud-
ies have often involved the use of semi- structured interviews, and 
comparatively fewer studies have used focus groups.28-32 A study by 
Bussières et al.32 was the only focus group study identified by the re-
search team that described methods used to assess the importance of 
domains with respect to the target behaviour. This involved the use 
of frequency counts (ie the number of times that beliefs/statements 
were mentioned per domain) as one of the assessment criteria.32 
Although frequency counts have commonly been used as a criterion 
to assess the importance of domains in TDF- based interview studies, 
there are challenges involved in applying this approach to the analy-
sis of focus group data. For example, in a focus group context, there 
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are many verbal and non- verbal ways that participants can indicate 
their agreement with other participants (eg short verbal responses, 
head nodding) which can be difficult to capture accurately from audio 
recordings.33,34 Hence, relying solely on strict frequency counts from 
the analysed transcripts of the audio recordings may underestimate 
the importance of a theoretical domain. To overcome this chal-
lenge, the research team also took into consideration the expression 
of strong beliefs (whereby an individual emphasized or re- iterated a 
belief) as an indicator of domain importance, in addition to the verbal 
agreement amongst participants in each group or similarities across 
focus groups. This adapted criterion (ie “evidence of verbal agree-
ment or strong beliefs expressed by an individual”) guided decisions 
regarding the importance of each domain to the target behaviour (ie 
adherence to multiple medications). Key domains to target in an in-
tervention were then selected based on the feasibility of overcoming 
barriers (or enhancing facilitators) in the proposed setting of commu-
nity pharmacies and using the wider project’s resources. All decisions 
involved a consensus- based approach.
2.3.3 | Stage 3: Mapping of key TDF domains to 
BCTs (intervention components)
The process for mapping key theoretical domains to BCTs was guided 
by methods reported by Cadogan et al.20 A mapping table produced by 
Cane et al.17 was used as the primary reference source as it provided 
the most up- to- date guidance on BCT mapping using the current 
available BCT taxonomy version 1 (BCTTv1).35 During group discus-
sions, a number of limitations were noted with the primary reference 
source.17 Firstly, no BCTs had been mapped to “memory, attention 
and decision processes” or “social/professional role and identity,” and 
secondly, the mapping process was carried out with TDF2, whereas 
the current study was based on TDF1. To overcome these limita-
tions, the original mapping matrix developed by Michie et al.18 was 
consulted as a secondary reference source. This matrix18 linked 35 
BCTs (from a provisional list of BCTs established prior to BCTTv135) 
to domains in TDF1 as agreed by four experts. A number of BCTs 
in the two reference sources17,18 had overlapping characteristics (eg 
“information about health consequences” and “information regarding 
behaviour, outcome”). To avoid potential duplication in the interven-
tion, the research team considered these BCTs to be equivalent and 
opted to retain the BCT labels reported using BCTTv1.35
The BCT selection process was completed by members of the 
research team and involved a consensus- based approach. Decisions 
were informed by the summary of findings from the content analysis 
of focus group data. In selecting BCTs to target key domains, two main 
factors were considered (i) the applicability of particular BCTs to the 
target group (ie older people prescribed multiple medications) and (ii) 
the expected feasibility of BCT delivery with regard to contextual con-
straints of the community pharmacy setting.20 As part of a linked study, 
GPs and community pharmacists took part in qualitative interviews 
F IGURE  1 An overview of the three stages involved in data analysis. aA domain was considered to be important if it met the criterion 
“evidence of verbal agreement or strong beliefs expressed by an individual”. bSelection was based on expected feasibility of BCT delivery in 
the proposed setting and applicability to target group. cNo BCTs were mapped to “Memory, attention and decision processes” and “Social/
professional role and identity” domains in the primary reference source
Stage 1: Idenfication of Stage 2: Idenfication of key Stage 3: Selecon of BCTs (intervention
determinants of behaviour TDF domains for behaviour change components)
Key
TDF: Theorecal Domains Framework 
BCT: Behaviour Change Technique 
Key TDF domains mapped to BCTs using 
primary reference source.17
Preliminary selecon of BCTs based on 
discussion among research team.b
Limitaons with primary reference source 
noted.c
Key TDF domains mapped to BCTs in
secondary reference source.18
Producon of a combined list of BCTs 
(from primary and secondary sources) 
that could target each key domain.
Consensus-based discussion to select 
BCTs to include in the intervenon.b
Review of barriers and facilitators 
within each TDF domain by research 
team.
Group-based discussion to assess the 
importance of each domain in the 
context of the target behaviour.a
Discussion of the feasibility of 
overcoming idenfied barriers (or 
enhancing facilitators) within the 
community pharmacy seng.
Consensus-based discussion to 
idenfy key domains to target with an 
intervenon.
Transcripon of focus group audio-
recordings.
In-depth familiarizaon process 
(listening to audio recordings and 
rereading transcripts).
Framework analyis: Focus group 
data coded to 12 domains of TDF by 
two independent researchers.
Content analysis: Emerging themes 
in each domain idenfied (i.e. 
barriers and facilitators).
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(n=30) which explored their views on prescribing and dispensing poly-
pharmacy to older patients, respectively. These study findings, which 
are reported in a separate publication,20 helped to provide contextual 
information that was relevant to the current intervention (eg time and 
resource restrictions in current practice). Potential implementation 
issues (eg likely BCT preparation and delivery time) were taken into 
consideration at this early stage of intervention development to help 
exclude BCTs that were unlikely to be feasible for delivery in primary 
care by community pharmacists.
3  | RESULTS
3.1 | Participant characteristics
Seven of the ten general practices that participated in the previous 
linked study20 agreed to facilitate patient recruitment, and seven 
focus groups were convened (one per practice). Overall, 50 partici-
pants (60% female) were recruited, with each focus group comprising 
between five and 10 participants and ranging in duration from 65- 
123 minutes (Table 1). Data saturation was reached by the seventh 
focus group as no new themes were emerging at this point.
3.2 | Summary of key findings from Stage 1 
(identification of determinants of adherence)
A wide range of reported barriers and facilitators of adherence to 
multiple medications were identified within each theoretical domain; 
these are presented in Table 2 together with illustrative quotes.
3.3 | Summary of key findings from Stage 2 
(Identification of key domains)
Based on the research team’s review of the summary findings from 
Stage 1, all 12 domains were considered to be important in respect 
to the target behaviour (adherence to multiple medications). Through 
group consensus, eight of the 12 domains were selected as key do-
mains to target as part of a community pharmacy- based intervention: 
“Knowledge,” “Beliefs about consequences,” “Motivation and goals,” 
“Environmental context and resources,” “Social influences,” “Memory, 
attention and decision processes,” “Behavioural regulation” and 
“Nature of the behaviours”. Four domains were not selected as key 
target domains: “Social/professional role and identity,” “Beliefs about 
capabilities,” “Skills” and “Emotion.”
3.4 | Summary of key findings from Stage 3 
(Mapping of key domains to BCTs)
Forty- one BCTs were identified from the two reference sources17,18 
and considered for inclusion in the intervention. Eleven BCTs were 
subsequently selected for inclusion in an intervention [“Information 
about health consequences,” “Feedback on behaviour,” “Goal- setting 
(outcome),” “Review of outcome goal,” “Goal- setting (behaviour),” 
“Review of behaviour goal,” “Action planning,” “Prompts and cues,” 
“Restructuring the physical environment,” “Social support or encour-
agement (general)” and “Self- monitoring of the behaviour”]. Table 3 
presents the selected 11 BCTs mapped to key TDF domains (Appendix 
S3 includes further details of BCTs that were not selected for inclu-
sion in the intervention).
4  | DISCUSSION
This article reports findings from the systematic process that was 
used to identify key theoretical determinants of adherence to multi-
ple medications in older people and select intervention components 
(BCTs) to include in an intervention for delivery by community phar-
macists. The focus group findings highlight the wide range of barriers 
and facilitators perceived to be influencing older patients’ adherence 
behaviour, and the subsequent challenge for researchers in selecting 
both key domains to target and intervention components (BCTs) to 
bring about behaviour change.20
Four domains were not selected because they did not contain bar-
riers/ facilitators that were considered feasible to target within the 
available project resources and selected setting of community phar-
macy. For example, under the “Skills” domain, patients discussed the 
physical skills involved in opening mediation packaging and swallowing 
oral dosage formulations. These are recognized issues that are import-
ant to consider in ensuring appropriate use of multiple medications 
in older people.36 However, it was beyond the scope of the current 
project to improve patients’ physical skills relating to manual dexterity 
or swallowing ability. Hence, the “Skills” domain was not considered 
for intervention targeting. Instead, it was intended that the barriers 
TABLE  1 Characteristics of focus 
groups Focus group 
number
Number of 
participants
Male:female 
ratio
Duration 
(minutes)
Health and social care 
trust area (urban/rural)
1 10 3:7 102 1 (urban)
2 9 5:4 123 2 (urban)
3 7 2:5 88 3 (rural)
4 6 2:4 87 4 (rural)
5 6 2:4 65 2 (urban)
6 7 3:4 84 4 (urban)
7 5 3:2 69 3 (rural)
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TABLE  2 Determinants (ie barriers and/or facilitators) of older patients’ adherence behaviour identified within each TDF domain and 
illustrative quotes
TDF domain
Determinants (ie barriers and/or facilitators) of 
adherence to multiple medications Illustrative quotes
Knowledge • Lack of/incorrect knowledge of clinical indication, 
treatment duration or administration timing (barrier)
• Lack of/incorrect knowledge of the consequences of 
adherence or non-adherence (barrier)
• Extent of knowledge on medication side-effects 
(barrier or facilitator)a
“I wasn’t aware, and I’ll have to read the boxes again. I wasn’t aware 
of, of the time of the day or night…” (FG07PT02) 
“You know, a build- up of this, that and the other, you just sort of 
wonder can that be good or would you be better off taking a 
break…” (FG05PT02) 
“Sometimes the less you know the better, just take it.” (FG05PT01)
Beliefs about 
consequences
• Concerns about medication side-effects/long-term 
consequences of adherence or non-adherence 
(barrier)
• Belief that missed doses cause no harm (barrier)
• Belief that medication is unnecessary and/or lacks 
benefit (barrier)
• Belief that non-adherence has negative outcomes  
(eg hospitalization, mortality) (facilitator)
• Belief that medication is necessary and/or beneficial 
(eg improves quality of life, prolongs survival) 
(facilitator)
• Return of symptoms (facilitator)
“Well, blood pressure is very serious, I would take my blood pressure 
tablet every day. I’m on aspirin, I take that every day. See this is why 
I laughed when I got the letter and it said, you know, ‘Four tablets 
plus’. I am officially down as four tablets plus but I don’t take four 
tablets plus…” (FG03PT06) 
“I remember at one stage thinking I don’t think them tablets are 
doing me any good, I would say to the wife, ‘You wouldn’t be taking 
them no more’. I said, ‘I want to stop, I don’t think they’re doing me a 
lot of good…’” (FG02PT04) 
“…I’ve never stopped taking them but I sort of wondered if I stopped 
taking these what would happen but I tried it for a wee while but my 
blood pressure went away up. And then it takes a wee while for the 
tablets to be effective again.” (FG04PT01)
Emotion • Anxiety about side-effects/long-term consequences 
of adherence or non-adherence (barrier) 
• Anxiety about potential consequences of non- 
adherence (facilitator) 
“Well, I would worry about the side effects but I know I have no 
choice but take them.” (FG01PT04) 
“I’d be afraid of not taking them, I don’t know what the effect would 
be but I’d be afraid if I didn’t take them that it would affect me 
badly.” (FG07PT02)
Skills • Lack of physical skills to take medications as 
prescribed (eg ability to swallow medications, poor 
manual dexterity) (barrier)
“But I couldn’t, I couldn’t actually physically get them out, [Out of the 
thing, yeah] trying to get the back open.” (FG01PT09)
“Sometimes it’s quite difficult to, to pop them out of the foil.” (FG06PT02)
Beliefs about 
capabilities
• Belief about lack of physical capability (see “Skills” 
domain) (barrier) 
• Belief that medication use is not difficult (facilitator) 
“And I would say, ‘Excuse me, I can’t take those, [Can’t swallow] no, 
can you give me those ones that’s in the water?’…” (FG01PT01) 
“But it’s the top, if you’ve one of those tops they’re impossible if 
you’ve arthritic hands.” (FG01PT06) 
“I’ve no difficulty there with anything…there, as long as I’m able to 
take the tablets that’s the main thing…” (FG04PT05)
Environmental 
context and 
resources
• Access to medications (eg at weekends) (barrier)
• Changing environment (eg on holidays, day trips) 
(barrier)
• Physical resources (eg MDS, medication lists) 
(facilitator)
“…you have to make sure you have everything with you and 
 sometimes you’d be in meetings or something like here and the time 
you’re supposed to take it is gone by.” (FG03PT03) 
“I get it in a bubble pack [MDS] for the week and he leaves it out 
morning and evening, it’s just so easy in case you forget them…” 
(FG05PT04)
Motivations 
and goals
• Goals to reduce the total number of prescribed 
medications (barrier)
• Relative priority placed on medications that patients 
deemed to be of greater importance (barrier/ 
facilitator)b
• High intrinsic motivation to take medications as 
prescribed (facilitator)
• Goals to avoid hospital admission, maintain driving 
licence, clinical goals (eg symptom control) (facilitator)
“You decide what’s the serious ones and if you run out of a lesser 
tablet, well it’s not as dangerous, you can wait till you get to the 
pharmacist, you know. There’s a couple of my tablets that, well I 
need to take them but they’re not as important if you know what I 
mean as the blood pressure tablets…” (FG03PT03) 
“Well I think it’s very important for me too because I would have…
kidney failure or kidney disease and I think if I didn’t do me things 
right I might end up in hospital again where I don’t want to be.” 
(FG07PT03)
Behavioural 
regulation
• Systems that alert patients to missed doses (eg MDS) 
(facilitator)
• Practical and reminder strategies (eg placement of 
medication in a visually prominent place) (facilitator)
• Action planning (eg planning administration times) 
(facilitator)
• Self-monitoring of medication use and outcomes (eg 
blood glucose, symptom control) (facilitator)
“And I put it [MDS] down beside the kettle because I know I’m going 
to the kettle in the mornings, the tablets are there for me.” 
(FG07PT03) 
“I have a wee weekly box and I take so many tablets in the morning 
they’re divided between two compartments but I do all my week’s 
drugs on a Sunday night so they’re all done.” (FG01PT09)
(Continues)
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identified under this domain would be addressed indirectly by ensur-
ing that appropriate types of formulations and medication packaging 
were issued to patients (“Environmental context and resources”).
This study contributes to the growing body of literature on the 
application of the TDF in designing behaviour change interventions. 
While the TDF was originally developed to investigate the implemen-
tation of evidence- based practices by HCPs,15 it is now being used to 
explore patient behaviours.37,38 This study highlights the usability of 
the TDF as the underpinning theoretical model in focus group stud-
ies examining patient behaviours. Incorporating a theory base into the 
development of this intervention will allow explicit links to be made 
between intervention components and outcomes and ultimately help 
to understand the causal mechanisms underlying the intervention’s 
effects.39
The importance of routine to patients’ adherence behaviour is con-
sistent with previous qualitative studies25,40,41 which, in contrast to 
the current study, were not underpinned by a theoretical framework 
of behaviour change. As “routine” was coded under the “Nature of the 
behaviours” domain, which has since been removed from the frame-
work in TDF2,24 the focus group findings support our rationale for the 
selection of TDF115 as the underpinning model for the current project. 
Based on the focus group findings, it was evident that the “Nature of 
the behaviours” domain would need to be targeted, albeit indirectly, in 
an intervention to improve adherence to multiple medications in older 
people. It is proposed that BCTs selected to target other key domains 
will influence the routine nature of patients’ adherence behaviours (eg 
“prompts/cues,” “self- monitoring of the behaviour”) and, hence, target 
the “Nature of behaviours” domain indirectly.42
This study represents a further advancement of the application 
of the TDF15,24 and BCT taxonomy (v1)35 in the development of 
patient- targeted behaviour change interventions. A recent study by 
McCullough et al.38 mapped key TDF domains to BCTs using the origi-
nal mapping protocol developed by Michie et al.18 In the current study, 
the work by Cane et al.17 served as the primary mapping reference 
source and provided the most recent guidance in completing the BCT 
mapping process.
As previously outlined, the project modelled the MRC frame-
work14 in that it endeavoured to incorporate both an evidence base 
and a theory base into the intervention development phase. In op-
erationalizing the MRC framework, we also considered practical 
TDF domain
Determinants (ie barriers and/or facilitators) of 
adherence to multiple medications Illustrative quotes
Memory, 
attention and 
decision 
processes
• Forgetting to take medications as prescribed (barrier)
• Paying attention to medications deemed to be of 
higher importance (barrier/facilitator)b
• Paying attention to medications when out of normal 
context (eg on holidays, at meetings) (facilitator)
• Making decisions regarding medication use without 
consulting a HCP (eg reducing doses, non- 
persistence) (barrier)
• Involving HCPs in decisions regarding medication use 
(facilitator)
“So obviously I’ve forgotten, not that I’m that fond of statins anyway 
because they keep giving me pains, they’re desperate.” (FG06PT07) 
“I have at several times…with different medications cut down to see 
how I can go, I’ve never actually stopped…that I cut it out altogether, 
no I haven’t done that.” (FG04PT02) 
“Sometimes when I go on holiday I don’t take my fluid one. I just- but 
it’s combined with my blood pressure tablet…so I’m cutting both of 
them out but I do, for a few days anyway.” (FG01PT06)
Social 
influences
• Social support/pressure from family (facilitator)
• Social support/pressure from HCPs (facilitator)
• Lack of (or withdrawal of) social support from family 
(eg death of spouse) (barrier)
“‘You’re not taking your tablet, I know by the look on your face’… that 
sort of reacts to you because the girl [Diabetic nurse] knows you and 
you know the girl, it’s not as if she’s a stranger.” (FG01PT01) 
“My wife passed away last Christmas and I, I find it difficult to 
manage [my] tablets. She remembered every time I had to take a 
tablet and sometimes I was going days without certain tablets…” 
(FG01PT10)
Social/ 
professional 
role and 
identity
• Patient autonomy (ie viewing medication use as their 
own responsibility) (facilitator)
“Everyone would be responsible for themselves.” (FG04PT06) 
“…I’m the one that’s been affected by it so… as far as I’m 
 concerned… it’s my responsibility to do it.” (FG06PT01)
Nature of the 
behaviours
• Having a personalized routine (eg linked to meal 
times) (facilitator)
• Lack of routine or ineffective routine (barrier)
• Return of symptoms (direct experience) (facilitator)
“Well, I used to worry about, as I say, taking the tablets and so I 
developed a wee routine, you know. Here’s me, I’ll take them this 
way. So I take the, the wee one in the morning and then start eating 
my porridge…” (FG02PT06) 
“It’s no difficulty for me because as soon as I have my breakfast into 
the kitchen, into the cupboard, get them out, that’s it. It’s just 
routine.” (FG01PT08)
HCP, Health- care professional; MDS, Monitored Dosage System.
aThis determinant could be a barrier or facilitator depending on the individual circumstances.
bThis determinant facilitates adherence to the medication the patient deems to be of greater importance but acts as a barrier to medications deemed to be 
less important.
TABLE  2  (Continued)
     |  145PATTON eT Al.
implementation issues during initial BCT selection. Failure to consider 
these practicalities at an early stage can result in “weaker interventions 
that are harder to evaluate, less likely to be implemented and less likely 
to be worth implementing.”14 Throughout the decision- making pro-
cess regarding BCT selection, the research team was conscious of the 
time constraints in primary care which have been well publicized.43-45 
Drawing on our previous experience of developing an intervention 
targeting HCPs,20 as well as knowledge of relevant literature that mul-
tifaceted interventions are not necessarily more effective in changing 
target behaviours than single- component interventions,46 we aimed to 
keep the intervention as simple as possible. It was clear that inclusion 
of all 41 identified BCTs would make the intervention too complex 
and impossible to implement in the proposed setting. Hence, it was 
beneficial if BCTs targeted multiple key domains and this was taken 
into consideration during the BCT selection process. For example, 
the BCT “Action planning” was selected instead of the BCT “Graded 
tasks, starting with easy tasks,” as the former targets three key do-
mains (“Motivation and goals,” “Behavioural regulation” and “Memory, 
attention and decision processes”), whereas the latter targets only one 
key domain (“Motivation and goals”).
The BCT “Threats” was considered to be an inappropriate 
method for attempting to change older patients’ “Beliefs about con-
sequences” of non- adherence. This is because threats can evoke 
negative emotions which could be detrimental to the patient- HCP re-
lationship, and this does not align with the person- centred approach 
to medicines optimization that is advocated by organizations such as 
the UK National Institute for Health and Care Excellence (NICE).47 
Conversely, the BCT “Information about health consequences” was 
considered more appropriate for the target intervention recipients 
(see Appendix S3 for further explanations for selection or non- 
selection of BCTs).
The “Nature of the behaviours” domain was the only domain that 
did not map directly to any BCTs in either reference source.17,18 This 
is because this domain is considered to be distinct from the other 
domains, in that it represents the “essential characteristics of the be-
haviour” (dependent variable), rather than a predictor of the behaviour 
Key TDF domain
Behaviour Change Techniques(BCTs) selected to target the TDF 
domain
Knowledge Information about health consequencesa /Information regarding 
behaviour, outcomeb
Feedback on behavioura
Beliefs about 
consequences
Self- monitoringa
Information regarding behaviour/outcomeb
Feedbackb
Environmental context and 
resources
Restructuring the physical environmenta/ Environmental changesb
Prompts and cuesa
Motivation and goals Goal- setting (outcome)a
Goal- setting (behaviour)a
Review of outcome goala
Review of behaviour goala
Goal/target specified: behaviour or outcomeb
Action planninga
Social processes of encouragement, pressure, supportb
Information regarding behaviour, outcomeb
Behavioural regulation Self- monitoring (of behaviour)a
Goal/target specified: behaviour or outcomeb
Planning, implementationb
Prompt/triggers/ cuesb
Memory, attention and 
decision processes
Self- monitoringb
Planning, implementationb
Prompts/trigger/cuesb
Social influences Social support or encouragement (general)a/ Social processes of 
encouragement, pressure, supportb
Nature of the behaviours None identifiedc
aIdentified from primary reference source.17
bIdentified from secondary reference source.18
cThis domain was not included in either reference source; therefore, no BCTs were mapped to this 
domain. This domain will be targeted indirectly using the selected BCTs that were mapped to the other 
key domains (eg BCT: prompts and cues that mapped to environmental context and resources).
TABLE  3 Final selection of BCTs to 
target each key domain and include as 
components of an intervention to improve 
adherence to multiple medications in older 
people
146  |     PATTON eT Al.
(independent variable).24 However, as discussed previously, it will be 
targeted indirectly with BCTs (eg “Prompts/cues”) selected to target 
other key TDF domains.42
As the methodology of TDF- based intervention development con-
tinues to evolve, guidelines on the “best practice” approach for se-
lecting BCTs to include in an intervention would serve as a valuable 
resource to those working in this field of research.
4.1 | Strengths and limitations
The details reported in this article follow guidelines48 produced by a 
Workgroup for Intervention Development and Evaluation Research 
(WIDER) which recommend reporting on: “1) The intervention develop-
ment; 2) The change techniques used in the intervention; 3) The causal 
processes targeted by these change techniques.” By making explicit links 
between the intervention components and key determinants of be-
haviour change, this will facilitate our understanding of how the inter-
vention exerts its effect. Specifying the intervention content in terms 
of BCTs from an established taxonomy (BCTTv1)35 will facilitate rep-
lication and implementation of the intervention in future evaluations 
and, ultimately, into clinical practice, if the intervention is shown to be 
effective. The study also followed previous recommendations on the 
effective application of the TDF.19
Due to the extensive reporting requirements that are now rec-
ommended to ensure that interventions can be replicated, we are 
unable to provide detailed descriptions in the current article of how 
BCTs will be delivered in an intervention.48,49 A future paper will de-
scribe how the 11 selected BCTs were operationalized in the design 
of an intervention so that it could be delivered to older people in 
the community pharmacy setting. The results from this study have 
provided important contextual information that will inform exactly 
how each BCT will be operationalized as part of a complex inter-
vention. The selection of intervention components in this study has 
focused on the patient’s perspective to taking several medications as 
prescribed, however, as part of the future testing of the intervention 
the views and opinions of those involved in intervention delivery (ie 
community pharmacists) will be sought to inform the need for any 
refinements.
As a limitation of the study, it must be noted that focus group 
participants were self- selected and their level of adherence was 
not formally measured. Nonetheless, variation in the sample of par-
ticipants was evident, ranging from those who reported no issues 
with adherence to those who reported frequent non- adherence be-
haviours. The inclusion of both adherent and non- adherent patients 
enabled the exploration of both facilitators and barriers to the target 
behaviour.
It must also be noted that the intervention development work is 
underpinned by a qualitative study. Although this allowed an in- depth 
exploration of the target behaviour, the findings are not readily gen-
eralizable to the wider population of older people in primary care. 
However, the sampling strategy incorporated participants from both 
urban and rural areas from across the regions of Northern Ireland 
which helps to increase the transferability of the focus group findings.
5  | CONCLUSIONS
Identifying key domains from focus group data and mapping to BCTs 
has provided the basis for designing an intervention to improve adher-
ence to multiple medications. Future work will focus on incorporating 
the selected BCTs into an intervention for community pharmacists to 
deliver to this group of patients. The intervention will undergo feasi-
bility testing at a later stage of the project before any larger- scale trial 
evaluation is conducted.
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